Effect of yoga-based lifestyle intervention on endothelial function and vascular ageing in adults with type 2 diabetes: a study protocol for a randomised controlled (Yoga V-AgE) trial Authors: Satish Gurunathrao Patil, Laxmi Ramchandra Patil, Vindya Vasu Shetty, Guru Praveen S, Dharani E, Manjunath Rajanna, Vadiraj H S, Lohit Kumbar, Kiran Ramchandra Aithal, Bharathi Gadad, Sheela Kudari, Sumaiya Sayed, Pooja Katti, Vijay Aravind Yenagi Published: 2026 ABSTRACT AbstractIntroductionDespite advances in diabetes care, cardiovascular disease (CVD) remains the leading cause of morbidity and mortality in type 2 diabetes mellitus (T2DM), with significant residual risk despite optimal glycaemic control. Targeting upstream vascular mechanisms beyond metabolic endpoints is therefore essential through more holistic and integrative approaches to effectively prevent cardiovascular complications in T2DM. Endothelial dysfunction plays a central role in accelerating atherosclerosis and premature vascular ageing in T2DM, thereby increasing the cardiovascular risk, making it a key therapeutic target. This study aims to rigorously evaluate the effect of a structured yoga-based lifestyle programme on endothelial function, markers of vascular ageing and quality of life in individuals with T2DM and to elucidate potential mechanisms of action through assessment of autonomic, inflammatory, oxidative and metabolic pathways.Method and analysisA prospective, four-arm, parallel-group, randomised, open-label, blinded end-point study will be conducted at a tertiary care hospital on a total of 248 (62 per arm) adults aged between 30 and 70 years and have a confirmed diagnosis of T2DM for at least 1 year. Three yoga-based intervention groups will receive different components of yoga-based lifestyle intervention in addition to standard medical care, and the control group will receive standard medical care alone. The yoga intervention will be delivered over 12 weeks, comprising supervised sessions twice weekly, supplemented by guided home practice. The primary outcome is the change in endothelial function assessed by flow-mediated dilatation. Secondary outcomes include arterial stiffness, vascular ageing markers, glycaemic and lipid profiles, autonomic function, oxidative stress, quality of life and cost of care. Outcome assessments will be performed at baseline, 3, 6 and 12 months, with outcome assessors blinded to group allocation. Data will be analysed according to the intention-to-treat principle. Analysis of covariance and mixed-effects models will assess intervention effects, with sensitivity analyses. Effect estimates and their 95% CIs will be reported.Ethics and disseminationThe study has received approval from the Institutional Ethics Committee of SDM College of Medical Sciences and Hospital, India (approval no. SDMIEC/2025/1075). The study findings will be disseminated through peer-reviewed scientific publications, presentations at national and international conferences and stakeholder meetings, with the aim of informing integrative strategies for effectively preventing cardiovascular complications in T2DM.Trial registration numberCTRI/2024/10/075712.Keywords: Diabetes Mellitus, Type 2; Treatment Outcome; MOLECULAR BIOLOGY; Exercise; Mindfulness; Cardiovascular Disease STRENGTHS AND LIMITATIONS OF THIS STUDY This prospective randomised controlled trial will evaluate the role of a yoga-based lifestyle intervention in vascular protection in type 2 diabetes mellitus (T2DM) under real-world conditions, with blinded outcome assessment. This prospective randomised controlled trial will evaluate the role of a yoga-based lifestyle intervention in vascular protection in type 2 diabetes mellitus (T2DM) under real-world conditions, with blinded outcome assessment. The study will comprehensively assess endothelial function, arterial stiffness, vascular ageing and haemodynamics using gold-standard methods to address a key evidence gap in yoga-based interventions for T2DM. The study will comprehensively assess endothelial function, arterial stiffness, vascular ageing and haemodynamics using gold-standard methods to address a key evidence gap in yoga-based interventions for T2DM. Integration of physiological, biochemical and molecular markers will enable in-depth evaluation of mechanistic pathways underlying metabolic and vascular changes. Integration of physiological, biochemical and molecular markers will enable in-depth evaluation of mechanistic pathways underlying metabolic and vascular changes. Comparison of three yoga models will allow component-specific analysis, although variable adherence to home-based practice may affect intervention fidelity. Comparison of three yoga models will allow component-specific analysis, although variable adherence to home-based practice may affect intervention fidelity. The findings of this study may not be generalisable to the broader T2DM population; rather, they are most applicable to individuals with T2DM without established cardiovascular disease. The findings of this study may not be generalisable to the broader T2DM population; rather, they are most applicable to individuals with T2DM without established cardiovascular disease. Introduction Type 2 diabetes mellitus (T2DM) is a multifactorial metabolic disorder characterised by insulin resistance, progressive β-cell dysfunction and chronic hyperglycaemia, and it represents a major global public health burden.1 2 Despite significant advances in diabetes care, cardiovascular disease (CVD) remains the leading cause of morbidity and mortality among individuals with T2DM.3–5 People with T2DM have a twofold to fourfold higher risk of cardiovascular (CV) events, largely attributable to accelerated atherosclerosis and premature vascular ageing.4–6 Although contemporary pharmacological therapies and risk-factor modification strategies have improved clinical outcomes, a substantial residual CV risk persists even under optimal glycaemic control.6 7 These observations highlight the need to target upstream vascular mechanisms, beyond metabolic endpoints alone, through more holistic and integrative approaches to effectively prevent CV complications in T2DM.8 Endothelial dysfunction (ED) represents an early and a central pathophysiological link between T2DM and the development of CVD and diabetes-related complications. In T2DM, chronic hyperglycaemia, insulin resistance and associated metabolic disturbances promote oxidative stress, low-grade inflammation and the formation of advanced glycation end products.9 10 These factors impair endothelial nitric oxide (NO) bioavailability by reducing endothelial nitric oxide synthase activity and increasing NO degradation, leading to diminished vasodilation, increased vascular tone and stiffening of arteries.11 12 Simultaneously, endothelial cells in T2DM exhibit a pro-inflammatory and pro-thrombotic phenotype, characterised by increased expression of adhesion molecules, enhanced leucocyte adhesion, platelet activation and impaired fibrinolysis.13 14 This dysfunctional endothelium plays a pivotal role in accelerating atherosclerosis and premature vascular ageing, thereby increasing the risk of major CV events such as coronary artery disease, stroke and peripheral arterial disease in individuals with T2DM.8 15 Moreover, ED contributes to microvascular complications of T2DM, including nephropathy, retinopathy and neuropathy, by disrupting microcirculatory blood flow, increasing vascular permeability and promoting tissue ischaemia.16 17 Thus, ED represents an early, unifying mechanism that connects metabolic abnormalities in T2DM to both macrovascular and microvascular complications, making it a critical therapeutic target for reducing CV risk, delaying vascular ageing and improving long-term outcomes in T2DM.18 Lifestyle modification, including physical activity, dietary management, stress reduction and behavioural changes, is a cornerstone of CVD risk reduction in T2DM. In recent years, yoga has emerged as a promising holistic strategy for improving cardiometabolic health. Yoga, an Indian ancient lifestyle practice, is a multicomponent practice integrating behavioural modulation, physical postures (āsana), breathing practices (prāṇāyāma), meditation and diet modulation. Several studies have reported improvements in glycaemic control, blood pressure, lipid profiles, inflammatory biomarkers and measures of autonomic function with yoga in individuals with T2DM and high CVD risk, suggesting potential benefits on vascular health.19–21 Mechanistically, yoga practices may enhance endothelial function by reducing oxidative stress and inflammation, improving insulin sensitivity, enhancing autonomic balance and increasing NO bioavailability.22–25 Despite these promising findings, the evidence on yoga’s direct effects on endothelial function, arterial stiffness and vascular ageing in people with T2DM remains limited and heterogeneous. Most existing studies are small, non-randomised or focused on intermediate cardiometabolic outcomes rather than validated measures of endothelial function (eg, flow-mediated dilatation (FMD)) or composite indices of vascular ageing (eg, aortic pulse wave velocity (PWV), augmentation index and telomere length). Furthermore, no adequately powered randomised controlled trial has systematically investigated the effects of integrated yoga-based lifestyle intervention on endothelial function and vascular ageing in T2DM. Moreover, the relative contributions of individual yoga components—physical activity or physical postures, breathing practices, meditation and a yoga-based diet—to improvements in vascular physiology have not been systematically delineated. There is also a paucity of mechanistic investigations that clarify how yoga-induced molecular and cellular changes translate into improvements in endothelial health and reduced CV risk in diabetes. Addressing these gaps is critical for establishing yoga-based lifestyle interventions as evidence-based adjuncts for CVD prevention in T2DM. Therefore, the present study aims to rigorously evaluate the effect of a structured integrated yoga-based lifestyle programme on endothelial function, markers of vascular ageing and quality of life in individuals with T2DM, and to elucidate potential mechanisms of action through assessment of autonomic, inflammatory, oxidative and metabolic pathways. By integrating clinical and mechanistic outcomes, this research seeks to advance our understanding of how holistic lifestyle interventions can modulate vascular health and reduce long-term CV risk in T2DM. Objectives of the study Primary objective To evaluate the effect of an integrated yoga-based lifestyle intervention on endothelial function in individuals with T2DM at 3 and 6 months. Secondary objectives To assess the protective effects of a yoga-based lifestyle intervention on vascular ageing in individuals with T2DM at 3 and 6 months. To assess the protective effects of a yoga-based lifestyle intervention on vascular ageing in individuals with T2DM at 3 and 6 months. To examine changes in glycaemic status, lipid profile, autonomic function, inflammatory markers and oxidative stress markers at 3 and 6 months from baseline. To examine changes in glycaemic status, lipid profile, autonomic function, inflammatory markers and oxidative stress markers at 3 and 6 months from baseline. To evaluate changes in quality of life, psychosocial stress, programme adherence and cost of care at 3, 6 and 12 months from baseline. To evaluate changes in quality of life, psychosocial stress, programme adherence and cost of care at 3, 6 and 12 months from baseline. To compare the effects of individual yoga components including yogāsanas, prāṇāyāma and meditation on metabolic-vascular axis in individuals with T2DM. To compare the effects of individual yoga components including yogāsanas, prāṇāyāma and meditation on metabolic-vascular axis in individuals with T2DM. Method and analysis Design Prospective, four-arm, parallel-group, Randomised, Open-label, Blinded End-point (PROBE) design. Study setting The study will be conducted at the Centre for Integrated Medicine and Research, SDM College of Medical Sciences and Hospital, a tertiary care centre equipped with facilities for clinical evaluation, standardised intervention delivery and outcome assessment. Study timeline Participant recruitment was commenced in November 2025, and the study is anticipated to be completed by November 2027, including data collection and follow-ups. Sample size determination This trial is designed as a confirmatory study with endothelial function, assessed by FMD, as the primary endpoint. The sample size was calculated based on the anticipated change in FMD from baseline. The sample size was calculated based on the primary outcome, namely the change in endothelial function assessed by FMD from baseline. Based on our prior studies22 23 evaluating the effects of yoga interventions on endothelial function, a mean difference of −1.23% in FMD with an SD of 1.64% was assumed. To detect this difference with a two-tailed α-level of 0.05 and 95% power, a minimum of 48 evaluable participants per group was required. Allowing for an anticipated dropout rate of 30%, a total of 248 participants (62 per arm) will be recruited. This sample size is expected to provide adequate statistical power to detect clinically meaningful improvements in endothelial function following the yoga-based intervention. Secondary outcomes, including markers of vascular ageing, arterial stiffness, glycaemic status, lipid profile, autonomic function, oxidative stress, quality of life, psychosocial stress, programme adherence and cost of care, will be analysed as exploratory outcomes, and the study is not specifically powered to detect differences in these parameters individually. Selection criteria Inclusion criteria Participants will be eligible for inclusion if they are adults aged between 30 and 70 years, have a confirmed diagnosis of T2DM for at least 1 year based on the American Diabetes Association criteria and are willing to provide written informed consent and comply with all study procedures and follow-up requirements. Exclusion criteria Participants will be excluded if they have hypertension, defined as systolic blood pressure >139 mm Hg and/or diastolic blood pressure >89 mm Hg, or if they are currently receiving antihypertensive medication. Individuals with a history of CVD or any other significant chronic illness, including chronic kidney disease, known to affect CV health will be excluded from the study. Those with neuromuscular disorders, significant joint pain or any musculoskeletal condition that would interfere with the safe performance of yoga practices will also be excluded. Additionally, individuals who have engaged in regular yoga practice, defined as 2–3 hours or more per week within the past 6 months, will not be eligible for participation. Randomisation and allocation Eligible participants identified through the screening process will be assigned a unique participant identification number. After confirmation of eligibility and completion of baseline investigations, participants will be randomised in a 1:1:1:1 ratio to either the intervention arm(s) or the control arm using a computer-generated randomisation sequence. Allocation concealment will be ensured using sequentially numbered, opaque, sealed envelopes prepared by an independent staff member not involved in recruitment or assessment. The envelopes will be opened sequentially only after participant enrolment. The allocated randomisation number will be used to identify participants throughout the study period. The assigned intervention will be initiated following randomisation. Blinding This study adopts a PROBE design. Given the inherent characteristics of the yoga programme intervention, neither the subjects nor the interventionists can be blinded to the allocation of treatment. In order to reduce the likelihood of introducing any analytical biases in the study, the statistical analysis of data shall be done by an independent biostatistician who will be blinded to the group allocations. Study protocol The overall flow of the study protocol is depicted in figure 1. Potential participants will undergo screening at visit 1, during which glycaemic status, blood urea and serum creatinine levels, blood pressure measurements and relevant clinical history will be documented to assess eligibility. Individuals meeting the predefined inclusion and exclusion criteria will be invited for baseline assessment. At visit 2, eligible participants will undergo comprehensive baseline investigations. Following completion of baseline assessments, participants will be randomised in a 1:1:1:1 ratio to one of three intervention arms or the control arm. Postintervention assessments will be conducted at 3 months, 6 months and 12 months (visits 3–5) to evaluate both short-term and long-term effects of the intervention. Follow-up assessments at 3 and 6 months will be conducted in person, while the 12-month follow-up will be conducted telephonically. Personnel involved in outcome assessment and data analysis will remain blinded to group allocation throughout the study period to maintain end-point blinding and minimise assessment bias (figure 1). Study protocol flow diagram. Intervention Participants will be randomised into four arms. Arm I will receive a yogāsanas (maintaining postures) module. Arm II will receive a prāṇāyāma (regulated breathing) and meditation module. Arm III will receive an integrated yoga module and arm IV will serve as the control group. The detailed structure of yoga intervention for the three study arms is provided in online supplemental tables S1–S6, respectively. Participants in arm I (study group) will receive a yoga programme consisting of loosening practices and yogāsanas, along with dietary modification, in addition to standard medical treatment (online supplemental tables S1 and S2). Participants in arm II (study group) will receive a yoga programme comprising loosening practices, prāṇāyāma and meditation, along with dietary modification and standard medical treatment (online supplemental tables S3 and S4). Participants in arm III (study group) will receive an integrated yoga programme that includes loosening practices, yogāsanas, prāṇāyāma and meditation, along with dietary modification and standard medical treatment (online supplemental tables S5 and S6). Participants in arm IV (control group) will receive usual standard medical treatment alone. For all three yoga intervention arms, participants will receive supervised yoga sessions (including dietary guidance) twice per week for a duration of 12 weeks, supplemented by guided daily home practice. All supervised sessions will be conducted under the supervision of an authorised and qualified yoga instructor, using a standardised intervention manual to ensure uniformity, safety and protocol adherence. Compliance monitoring Compliance will be verified by performing random checks through calls placed periodically without any prior notice from individuals independent of delivering the intervention and by reviewing the practice logs/diaries kept by participants and the attendance records, where necessary. Follow-up calls and standardised instructions will be provided to encourage adherence. Adherence monitoring and participant engagement Study group Adherence to the Yoga V-AgE intervention will be monitored throughout the study using multiple methods. Attendance at supervised yoga sessions will be recorded by study staff. Compliance with home-based practice will be assessed using a structured daily practice log maintained by participants, documenting the duration, frequency and components of yoga practice. Participant engagement and continuity of practice will be supported through periodic follow-up telephone calls, scheduled virtual reinforcement sessions and access to standardised audio-visual instructional materials to facilitate correct and consistent home practice. Adherence to home-based yoga will be intermittently verified through optional photo or video documentation and/or demonstration of selected practices during follow-up visits. Participants will be considered adherent if they complete at least 75% of the prescribed supervised and home-based sessions. Periodic review of practice logs and random compliance checks will be conducted to ensure fidelity to the intervention protocol. The intervention will be delivered by trained research fellows who are yoga and naturopathy physicians, with at least 2 years of experience in clinical research or patient education. Control group Participants allocated to the control arm will receive usual standard medical care alone, as per institutional and national clinical guidelines, without exposure to any structured yoga intervention or additional educational sessions. No supervised exercise or yoga-based practices will be provided as part of the study protocol for this group. Routine clinical follow-up and medical management will continue as advised by the treating physician. Outcome measures Primary outcome The primary outcome of the study is the change in endothelium-dependent FMD assessed at 3 and 6 months following the intervention, compared with baseline values. Secondary outcomes Secondary outcomes include changes from baseline to 3 and 6 months in measures of vascular ageing indices, arterial stiffness, glycaemic parameters, lipid profile, autonomic function, endothelial biomarkers, oxidative stress markers and antioxidant status. Secondary outcomes include changes from baseline to 3 and 6 months in measures of vascular ageing indices, arterial stiffness, glycaemic parameters, lipid profile, autonomic function, endothelial biomarkers, oxidative stress markers and antioxidant status. Additional secondary outcomes include changes in health-related quality of life, psychosocial stress levels, cost of care and adherence to the intervention, evaluated over a follow-up period of up to 1 year (3, 6 and 12 months). Additional secondary outcomes include changes in health-related quality of life, psychosocial stress levels, cost of care and adherence to the intervention, evaluated over a follow-up period of up to 1 year (3, 6 and 12 months). Methods of data collection Data will be collected systematically using standardised and validated instruments by trained research personnel following uniform operating procedures to ensure data quality and reproducibility. Demographic and clinical characteristics Baseline demographic and clinical information will be recorded using a structured case record form. Variables will include age, sex, educational status, occupation, medical history, duration of T2DM, family history of CVD and T2DM, history of smoking or tobacco use, alcohol consumption and current medication use, including antidiabetic and lipid-lowering therapies. Baseline demographic and clinical information will be recorded using a structured case record form. Variables will include age, sex, educational status, occupation, medical history, duration of T2DM, family history of CVD and T2DM, history of smoking or tobacco use, alcohol consumption and current medication use, including antidiabetic and lipid-lowering therapies. Physical activity assessment: physical activity levels will be assessed using the validated International Physical Activity Questionnaire, which captures the frequency, duration and intensity of physical activity across work-related, transport-related, household and leisure-time domains.26 Physical activity assessment: physical activity levels will be assessed using the validated International Physical Activity Questionnaire, which captures the frequency, duration and intensity of physical activity across work-related, transport-related, household and leisure-time domains.26 Dietary assessment: dietary intake will be evaluated using a Food Frequency Questionnaire.27 Dietary assessment: dietary intake will be evaluated using a Food Frequency Questionnaire.27 Sleep assessment: sleep quality and disturbances will be assessed using the Pittsburgh Sleep Quality Index, a validated tool.28 Sleep assessment: sleep quality and disturbances will be assessed using the Pittsburgh Sleep Quality Index, a validated tool.28 Stress and mental well-being: psychological stress and mental well-being will be evaluated using validated self-report instruments. Perceived stress will be assessed using the Perceived Stress Scale,29 while overall mental well-being will be measured using the WHO-5 Well-Being Index,30 which screens for psychological distress and depressive symptoms. Stress and mental well-being: psychological stress and mental well-being will be evaluated using validated self-report instruments. Perceived stress will be assessed using the Perceived Stress Scale,29 while overall mental well-being will be measured using the WHO-5 Well-Being Index,30 which screens for psychological distress and depressive symptoms. Diabetes-specific quality of life: quality of life specific to individuals with diabetes will be assessed using the Quality-of-Life Instrument for Indian Diabetes Patients, which evaluates physical health, emotional well-being, treatment satisfaction, financial concerns and social functioning.31 Diabetes-specific quality of life: quality of life specific to individuals with diabetes will be assessed using the Quality-of-Life Instrument for Indian Diabetes Patients, which evaluates physical health, emotional well-being, treatment satisfaction, financial concerns and social functioning.31 Anthropometry and obesity indices: anthropometric measurements will be obtained using standardised protocols. Height and weight will be measured to calculate body mass index (BMI, kg/m²). Waist circumference, hip circumference and waist-to-hip ratio will be measured using a non-stretchable measuring tape to assess central obesity. Anthropometry and obesity indices: anthropometric measurements will be obtained using standardised protocols. Height and weight will be measured to calculate body mass index (BMI, kg/m²). Waist circumference, hip circumference and waist-to-hip ratio will be measured using a non-stretchable measuring tape to assess central obesity. Biochemical assessments: fasting venous blood samples will be collected following an overnight fast and analysed using standardised laboratory procedures.Diabetes profile: glycaemic status will be assessed by measuring fasting blood glucose (hexokinase method), glycosylated haemoglobin by high-performance liquid chromatography method and fasting insulin levels using ELISA method.Oxidative stress and antioxidant status: oxidative stress will be evaluated by estimating serum malondialdehyde levels as a marker of lipid peroxidation using the thiobarbituric acid reactive substances assay.32 Endogenous antioxidant defence will be assessed by measuring serum superoxide dismutase activity24 33 and total antioxidant capacity.34Lipid profile: the lipid profile will include measurements of total cholesterol, triglycerides, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol, which will be quantified using automated clinical chemistry analysers following standard enzymatic methods.Renal function parameters: serum urea and creatinine levels will be assessed as indicators of renal function using automated clinical chemistry analysers. Biochemical assessments: fasting venous blood samples will be collected following an overnight fast and analysed using standardised laboratory procedures. Diabetes profile: glycaemic status will be assessed by measuring fasting blood glucose (hexokinase method), glycosylated haemoglobin by high-performance liquid chromatography method and fasting insulin levels using ELISA method. Diabetes profile: glycaemic status will be assessed by measuring fasting blood glucose (hexokinase method), glycosylated haemoglobin by high-performance liquid chromatography method and fasting insulin levels using ELISA method. Oxidative stress and antioxidant status: oxidative stress will be evaluated by estimating serum malondialdehyde levels as a marker of lipid peroxidation using the thiobarbituric acid reactive substances assay.32 Endogenous antioxidant defence will be assessed by measuring serum superoxide dismutase activity24 33 and total antioxidant capacity.34 Oxidative stress and antioxidant status: oxidative stress will be evaluated by estimating serum malondialdehyde levels as a marker of lipid peroxidation using the thiobarbituric acid reactive substances assay.32 Endogenous antioxidant defence will be assessed by measuring serum superoxide dismutase activity24 33 and total antioxidant capacity.34 Lipid profile: the lipid profile will include measurements of total cholesterol, triglycerides, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol, which will be quantified using automated clinical chemistry analysers following standard enzymatic methods. Lipid profile: the lipid profile will include measurements of total cholesterol, triglycerides, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol, which will be quantified using automated clinical chemistry analysers following standard enzymatic methods. Renal function parameters: serum urea and creatinine levels will be assessed as indicators of renal function using automated clinical chemistry analysers. Renal function parameters: serum urea and creatinine levels will be assessed as indicators of renal function using automated clinical chemistry analysers. Assessment of endothelial function: endothelial function will be evaluated using both functional vascular imaging and circulating biomarkers.Endothelium-dependent FMD of the brachial artery will be assessed using high-resolution colour Doppler ultrasound following a standardised reactive hyperaemia protocol (ECUBE 8 LE, ALPINION Medical Systems, South Korea). Endothelial function will be expressed as the percentage change in arterial diameter from baseline.35 36Carotid intima-media thickness will be measured using colour Doppler ultrasound as an index of subclinical atherosclerosis and ED (ECUBE 8 LE, ALPINION Medical Systems).36Circulating endothelial biomarkers include estimation of serum total NO concentration using the Griess reaction method following serum deproteinisation37 and endothelin-1 using commercially available ELISA kits. Assessment of endothelial function: endothelial function will be evaluated using both functional vascular imaging and circulating biomarkers. Endothelium-dependent FMD of the brachial artery will be assessed using high-resolution colour Doppler ultrasound following a standardised reactive hyperaemia protocol (ECUBE 8 LE, ALPINION Medical Systems, South Korea). Endothelial function will be expressed as the percentage change in arterial diameter from baseline.35 36 Endothelium-dependent FMD of the brachial artery will be assessed using high-resolution colour Doppler ultrasound following a standardised reactive hyperaemia protocol (ECUBE 8 LE, ALPINION Medical Systems, South Korea). Endothelial function will be expressed as the percentage change in arterial diameter from baseline.35 36 Carotid intima-media thickness will be measured using colour Doppler ultrasound as an index of subclinical atherosclerosis and ED (ECUBE 8 LE, ALPINION Medical Systems).36 Carotid intima-media thickness will be measured using colour Doppler ultrasound as an index of subclinical atherosclerosis and ED (ECUBE 8 LE, ALPINION Medical Systems).36 Circulating endothelial biomarkers include estimation of serum total NO concentration using the Griess reaction method following serum deproteinisation37 and endothelin-1 using commercially available ELISA kits. Circulating endothelial biomarkers include estimation of serum total NO concentration using the Griess reaction method following serum deproteinisation37 and endothelin-1 using commercially available ELISA kits. Vascular ageing and arterial stiffness: vascular ageing will be comprehensively assessed using a combination of validated non-invasive vascular measures (arterial stiffness) and molecular biomarkers reflecting structural, functional and biological aspects of vascular ageing.Arterial PWV: central and peripheral arterial stiffness will be assessed using PWV indices obtained from validated non-invasive devices. Carotid-femoral PWV will be measured using the ARTSENS Plus system (Healthcare Technology Innovation Centre, IIT Madras, India),38 while brachial-ankle PWV will be assessed using the Periscope device (Genesis Medical Systems, India).25Aortic augmentation index: wave reflection will be assessed using the augmentation index, normalised to heart rate, as an indicator of functional arterial stiffness and vascular load (Periscope).25 These indices collectively reflect large-artery stiffness and arterial wave propagation characteristics.Ankle-brachial index (ABI), a marker of peripheral arterial disease and systemic atherosclerosis, will be assessed by simultaneous measurement of systolic blood pressure at the brachial and ankle arteries using an automated device (Periscope). ABI will be calculated as the ratio of ankle-to-brachial systolic blood pressure.25Telomere length: biological vascular ageing will be assessed by measuring relative telomere length using a quantitative real-time PCR (qRT-PCR) method. Genomic DNA will be extracted from peripheral blood leucocytes using a commercial DNA extraction kit, and DNA concentration and purity will be evaluated spectrophotometrically. Telomere length will be expressed as the ratio of telomeric repeat copy number (T) to that of a single-copy reference gene (S; 36B4). All qRT-PCR reactions will be performed in triplicate using SYBR Green chemistry and cycle threshold values will be used for subsequent analysis. Vascular ageing and arterial stiffness: vascular ageing will be comprehensively assessed using a combination of validated non-invasive vascular measures (arterial stiffness) and molecular biomarkers reflecting structural, functional and biological aspects of vascular ageing. Arterial PWV: central and peripheral arterial stiffness will be assessed using PWV indices obtained from validated non-invasive devices. Carotid-femoral PWV will be measured using the ARTSENS Plus system (Healthcare Technology Innovation Centre, IIT Madras, India),38 while brachial-ankle PWV will be assessed using the Periscope device (Genesis Medical Systems, India).25 Arterial PWV: central and peripheral arterial stiffness will be assessed using PWV indices obtained from validated non-invasive devices. Carotid-femoral PWV will be measured using the ARTSENS Plus system (Healthcare Technology Innovation Centre, IIT Madras, India),38 while brachial-ankle PWV will be assessed using the Periscope device (Genesis Medical Systems, India).25 Aortic augmentation index: wave reflection will be assessed using the augmentation index, normalised to heart rate, as an indicator of functional arterial stiffness and vascular load (Periscope).25 These indices collectively reflect large-artery stiffness and arterial wave propagation characteristics. Aortic augmentation index: wave reflection will be assessed using the augmentation index, normalised to heart rate, as an indicator of functional arterial stiffness and vascular load (Periscope).25 These indices collectively reflect large-artery stiffness and arterial wave propagation characteristics. Ankle-brachial index (ABI), a marker of peripheral arterial disease and systemic atherosclerosis, will be assessed by simultaneous measurement of systolic blood pressure at the brachial and ankle arteries using an automated device (Periscope). ABI will be calculated as the ratio of ankle-to-brachial systolic blood pressure.25 Ankle-brachial index (ABI), a marker of peripheral arterial disease and systemic atherosclerosis, will be assessed by simultaneous measurement of systolic blood pressure at the brachial and ankle arteries using an automated device (Periscope). ABI will be calculated as the ratio of ankle-to-brachial systolic blood pressure.25 Telomere length: biological vascular ageing will be assessed by measuring relative telomere length using a quantitative real-time PCR (qRT-PCR) method. Genomic DNA will be extracted from peripheral blood leucocytes using a commercial DNA extraction kit, and DNA concentration and purity will be evaluated spectrophotometrically. Telomere length will be expressed as the ratio of telomeric repeat copy number (T) to that of a single-copy reference gene (S; 36B4). All qRT-PCR reactions will be performed in triplicate using SYBR Green chemistry and cycle threshold values will be used for subsequent analysis. Telomere length: biological vascular ageing will be assessed by measuring relative telomere length using a quantitative real-time PCR (qRT-PCR) method. Genomic DNA will be extracted from peripheral blood leucocytes using a commercial DNA extraction kit, and DNA concentration and purity will be evaluated spectrophotometrically. Telomere length will be expressed as the ratio of telomeric repeat copy number (T) to that of a single-copy reference gene (S; 36B4). All qRT-PCR reactions will be performed in triplicate using SYBR Green chemistry and cycle threshold values will be used for subsequent analysis. CV haemodynamics: CV haemodynamic parameters will be assessed using standardised non-invasive techniques.Resting heart rate and brachial blood pressure will be measured using a calibrated automated digital blood pressure monitoring device (Omron HEM 7124).Central arterial pressure will be measured non-invasively using the ARTSENS Plus system, a validated, operator-independent device based on high-resolution ultrasound wall-tracking technology. The device captures real-time carotid artery diameter waveforms and applies automated algorithms to derive central (carotid) systolic, diastolic and pulse pressure values. Measurements will be obtained with participants in the supine position after at least 10 min of rest in a quiet, temperature-controlled environment. Multiple recordings will be taken, and the average of three consecutive, high-quality readings will be used for analysis to ensure reliability and reproducibility. The device also enables simultaneous assessment of carotid arterial stiffness indices, facilitating comprehensive evaluation of central haemodynamics.38Rate pressure product (RPP) also known as double product (heart rate×systolic blood pressure), is a non-invasive index of myocardial workload and oxygen demand. RPP reflects the amount of work the heart performs and correlates with myocardial oxygen consumption. Higher values indicate increased cardiac workload and greater oxygen demand, making it a useful parameter in CV risk assessment and evaluation of therapeutic interventions.39Cardiac function: cardiac systolic and diastolic functions will be evaluated using arterial waveform analysis, by measuring left ventricular ejection time, systolic upstroke time and diastolic time (Periscope).39 CV haemodynamics: CV haemodynamic parameters will be assessed using standardised non-invasive techniques. Resting heart rate and brachial blood pressure will be measured using a calibrated automated digital blood pressure monitoring device (Omron HEM 7124). Resting heart rate and brachial blood pressure will be measured using a calibrated automated digital blood pressure monitoring device (Omron HEM 7124). Central arterial pressure will be measured non-invasively using the ARTSENS Plus system, a validated, operator-independent device based on high-resolution ultrasound wall-tracking technology. The device captures real-time carotid artery diameter waveforms and applies automated algorithms to derive central (carotid) systolic, diastolic and pulse pressure values. Measurements will be obtained with participants in the supine position after at least 10 min of rest in a quiet, temperature-controlled environment. Multiple recordings will be taken, and the average of three consecutive, high-quality readings will be used for analysis to ensure reliability and reproducibility. The device also enables simultaneous assessment of carotid arterial stiffness indices, facilitating comprehensive evaluation of central haemodynamics.38 Central arterial pressure will be measured non-invasively using the ARTSENS Plus system, a validated, operator-independent device based on high-resolution ultrasound wall-tracking technology. The device captures real-time carotid artery diameter waveforms and applies automated algorithms to derive central (carotid) systolic, diastolic and pulse pressure values. Measurements will be obtained with participants in the supine position after at least 10 min of rest in a quiet, temperature-controlled environment. Multiple recordings will be taken, and the average of three consecutive, high-quality readings will be used for analysis to ensure reliability and reproducibility. The device also enables simultaneous assessment of carotid arterial stiffness indices, facilitating comprehensive evaluation of central haemodynamics.38 Rate pressure product (RPP) also known as double product (heart rate×systolic blood pressure), is a non-invasive index of myocardial workload and oxygen demand. RPP reflects the amount of work the heart performs and correlates with myocardial oxygen consumption. Higher values indicate increased cardiac workload and greater oxygen demand, making it a useful parameter in CV risk assessment and evaluation of therapeutic interventions.39 Rate pressure product (RPP) also known as double product (heart rate×systolic blood pressure), is a non-invasive index of myocardial workload and oxygen demand. RPP reflects the amount of work the heart performs and correlates with myocardial oxygen consumption. Higher values indicate increased cardiac workload and greater oxygen demand, making it a useful parameter in CV risk assessment and evaluation of therapeutic interventions.39 Cardiac function: cardiac systolic and diastolic functions will be evaluated using arterial waveform analysis, by measuring left ventricular ejection time, systolic upstroke time and diastolic time (Periscope).39 Cardiac function: cardiac systolic and diastolic functions will be evaluated using arterial waveform analysis, by measuring left ventricular ejection time, systolic upstroke time and diastolic time (Periscope).39 Biomarkers of vascular inflammation: markers of vascular inflammation, including high-sensitivity C reactive protein and tumour necrosis factor-alpha, will be quantified using commercially available ELISA kits. Biomarkers of vascular inflammation: markers of vascular inflammation, including high-sensitivity C reactive protein and tumour necrosis factor-alpha, will be quantified using commercially available ELISA kits. Assessment of autonomic nervous system function: sympathetic and parasympathetic activity will be assessed using heart rate variability (HRV). A 5 min short-term ECG recording will be obtained in the standard limb lead II configuration using a digital polygraph (Niviqure, India). The recorded R-R intervals will be analysed using frequency-domain methods with HRV analysis software developed by the Biomedical Signal Analysis Group at the University of Kuopio, Finland. Low-frequency (LF) power will be interpreted as an index of sympathetic modulation, high-frequency (HF) power as an index of parasympathetic (vagal) activity and the LF/HF ratio as a measure of sympathovagal balance.27 40 Assessment of autonomic nervous system function: sympathetic and parasympathetic activity will be assessed using heart rate variability (HRV). A 5 min short-term ECG recording will be obtained in the standard limb lead II configuration using a digital polygraph (Niviqure, India). The recorded R-R intervals will be analysed using frequency-domain methods with HRV analysis software developed by the Biomedical Signal Analysis Group at the University of Kuopio, Finland. Low-frequency (LF) power will be interpreted as an index of sympathetic modulation, high-frequency (HF) power as an index of parasympathetic (vagal) activity and the LF/HF ratio as a measure of sympathovagal balance.27 40 Cost of care assessment: the economic burden of T2DM will be evaluated through a detailed cost-of-care assessment. Outpatient costs will include clinic visits, diagnostic investigations, medications, transportation and food expenses. Inpatient costs will include hospital or emergency admissions, length of hospital stay, treatment and medication costs, transportation, food and escort-related expenses. Sources of healthcare financing and indirect costs, such as wage loss and missed workdays, will also be documented. All costs will be reported in Indian rupees and expressed as mean annual expenditure per participant. Cost of care assessment: the economic burden of T2DM will be evaluated through a detailed cost-of-care assessment. Outpatient costs will include clinic visits, diagnostic investigations, medications, transportation and food expenses. Inpatient costs will include hospital or emergency admissions, length of hospital stay, treatment and medication costs, transportation, food and escort-related expenses. Sources of healthcare financing and indirect costs, such as wage loss and missed workdays, will also be documented. All costs will be reported in Indian rupees and expressed as mean annual expenditure per participant. Statistical analysis plan All statistical analyses will be performed according to the intention-to-treat principle, including all randomised participants in the groups to which they were originally assigned, irrespective of adherence to the intervention protocol. A per-protocol analysis including participants meeting predefined adherence criteria will be conducted as a supportive sensitivity analysis. Statistical significance for the primary confirmatory analysis will be assessed using a two-sided alpha level of 0.05. Baseline characteristics will be summarised by study group using mean±SD or median (IQR) for continuous variables depending on data distribution and frequencies and percentages for categorical variables. Baseline comparability between groups will be assessed descriptively. Normality of continuous variables will be evaluated using the Shapiro-Wilk test, Q-Q plots, histograms and assessment of skewness and kurtosis. Variables demonstrating substantial deviation from normality will be analysed using suitable non-parametric methods. The primary endpoint is the change in endothelial function, assessed by FMD, from baseline to the end of the intervention. The primary confirmatory hypothesis is that the Integrated Yoga Lifestyle intervention (arm III) will result in greater improvement in FMD compared with the control group (arm IV). The primary analysis will compare postintervention FMD between the Integrated Yoga Lifestyle arm and the control arm using analysis of covariance (ANCOVA), with postintervention FMD as the dependent variable, treatment group as the fixed factor and baseline FMD as a covariate. Additional prespecified covariates, including age, sex, BMI, baseline blood glucose and duration of diabetes, may be included where appropriate. Adjusted mean differences, effect sizes and corresponding 95% CIs will be reported. An overall four-group ANCOVA will also be performed to evaluate the presence of any difference in the treatment effect across study arms. However, this analysis will be considered supportive and exploratory and will not alter the interpretation of the primary confirmatory comparison. To better understand the relative contribution of different components of the intervention, additional between-group comparisons will be conducted on an exploratory basis. These comparisons may include: arm I versus control; arm II versus control; arm III versus arm I; arm III versus arm II; arm I versus arm II. Where these analyses are performed, appropriate adjustment for multiple comparisons (Bonferroni or Holm-Bonferroni correction) will be applied. Secondary outcomes (include markers of vascular ageing, arterial stiffness, glycaemic status, lipid profile, autonomic function, oxidative stress, quality of life, psychosocial stress, programme adherence and cost of care) will be analysed on an exploratory basis because the study is not specifically powered to detect differences in these individual endpoints. For continuous secondary outcomes measured at baseline and postintervention, ANCOVA models adjusting for baseline values will be used to estimate between-group differences. For categorical outcomes, χ2 tests or Fisher’s exact tests will be applied as appropriate. Results will be presented as adjusted mean differences with 95% CIs. Interpretation will focus primarily on the magnitude and precision of effects rather than statistical significance alone. For outcomes assessed at multiple time points, longitudinal changes will be analysed using linear mixed-effects models with random participant-level intercepts to account for repeated measurements. Fixed effects will include treatment group, time and treatment group×time interaction. These models allow inclusion of participants with incomplete follow-up data and provide valid estimates under the missing-at-random assumption. Where assumptions required for mixed-effects modelling are not satisfied, repeated-measures ANOVA with Greenhouse-Geisser correction may be employed for normally distributed variables. Appropriate non-parametric longitudinal methods will be considered for substantially skewed outcomes. As one of the objectives of the study is to investigate potential mechanisms underlying the effects of yoga-based interventions on vascular health, exploratory mechanistic analyses will be conducted. Associations between changes in FMD and changes in arterial stiffness, vascular ageing markers, autonomic function, oxidative stress biomarkers, metabolic parameters, psychosocial measures and adherence variables will be examined using correlation and regression analyses. Exploratory mediation analyses may also be performed to evaluate whether improvements in autonomic regulation, oxidative stress, vascular stiffness, metabolic status or psychosocial well-being mediate the effects of the intervention on vascular health in T2DM. The extent and pattern of missing data will be examined before analysis. If missing data exceed 5%, multiple imputation using chained equations will be performed under the assumption that data are missing at random. Sensitivity analyses comparing complete-case and imputed datasets will be undertaken to assess the robustness of study findings. For all analyses, effect estimates and their 95% CIs will be reported. Continuous outcomes will be summarised using adjusted mean differences and standardised effect sizes where appropriate. Emphasis will be placed on both statistical significance and clinical relevance. All analyses will be conducted using IBM SPSS Statistics (V.30). A detailed Statistical Analysis Plan, including definitions of analysis populations, handling of protocol deviations, management of missing data and specification of exploratory analyses, will be finalised before database lock and prior to unblinding of the study groups for the final statistical analyses. Ethics and dissemination The study has obtained approval from the Institutional Ethics Committee of SDM College of Medical Sciences and Hospital, India (approval no. SDMIEC/2025/1075) and is registered with the Clinical Trials Registry of India (CTRI/2024/10/075712). Study conduct and participant safety will be overseen by a Trial Steering Committee comprising experienced clinicians and research faculty independent of day-to-day trial implementation. The committee will periodically review study progress, protocol adherence and any adverse events. Written informed consent will be obtained from all participants prior to enrolment. Participant confidentiality will be strictly maintained, with access to study data restricted to the principal investigator and co-principal investigator, in accordance with institutional and regulatory guidelines. Criteria for discontinuation and safety monitoring Participants will be withdrawn from the study if they voluntarily withdraw consent at any time, are unable to continue or adhere to the assigned intervention or experience any adverse event necessitating discontinuation of the intervention, as determined by the study physician. Although the yoga-based intervention is generally safe, individuals with T2DM may experience occasional hypoglycaemia, blood pressure fluctuations, dizziness, fatigue or musculoskeletal discomfort. To minimise these risks, all sessions will be conducted under the supervision of trained yoga professionals, with appropriate posture modifications and rest as required. Participant safety will be monitored by assessing blood pressure, heart rate and capillary blood glucose (when indicated) before and after supervised sessions, along with observation for symptoms such as dizziness, palpitations, sweating or musculoskeletal pain. Any participant developing clinically significant symptoms will have the session immediately discontinued and receive medical evaluation. All adverse events will be documented, managed and monitored by the principal investigator and the Data Safety Monitoring Board (DSMB). A predefined adverse event reporting protocol will be followed. All reported events will be recorded and periodically reviewed by the DSMB to ensure participant safety and maintain data integrity throughout the study. Supplementary material Acknowledgements The authors would like to thank the Centre for Integrated Medicine and Research (CIMR), Department of Endocrinology and Department of General Medicine of SDM College of Medical Sciences and Hospital, Karnataka, India; the Multi-Disciplinary Research Unit of Dharwad Institute for Mental Health and Neurosciences (DIMHANS), Karnataka, India and the Central Research Institute of Yoga and Naturopathy (CRIYN), Karnataka, India, for providing the infrastructure, support and facilities required for the development of the protocol and conduct of this study. The authors would also like to thank Dimple Kondal, a biostatistician at the Centre for Chronic Disease Control, New Delhi, for assisting the team in preparing the statistical analysis plan. The authors would like to thank the yoga instructors, research fellows and technical staff involved in participant recruitment, intervention delivery and outcome assessments for their contributions to the study implementation. The authors would also like to acknowledge the anticipated participation and cooperation of the study participants. Footnotes Funding: The trial is funded by the Ministry of AYUSH, Government of India, under the Ayurgyan scheme (S-14012/01/2024). Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (https://doi.org/10.1136/bmjopen-2026-119948). Provenance and peer review: Not commissioned; externally peer reviewed. Patient consent for publication: Consent obtained directly from patient(s). Patient and public involvement: Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research. References Supplementary Materials